Project is Aimed at Developing New Screening Methods and Holds Significant Potential for Early Detection Blood Test for Nation's 4th Leading Cancer
Killer - Biomarker Project holds significant potential for new screening and diagnostic interventions for the disease, including a blood test to detect
the disease before even the most sophisticated scans - Consortium, comprised of Canary Foundation, Dana-Farber Cancer Institute, University of California at San Francisco and Van Andel Research Institute - Biomarker Development Project is expected to form the basis for future
studies evaluating antibodies for use in early detection tests, diagnostics, imaging, and therapeutic targets for the nation's fourth
BETHPAGE, N.Y., March 27 /PRNewswire/ -- The Lustgarten Foundation for Pancreatic Cancer Research, the largest private foundation dedicated exclusively to supporting pancreatic cancer research, will tomorrow hold a kick-off Consortium meeting in Chicago to launch a $1.25 million commitment to create antibodies for promising biomarker targets for pancreatic cancer, the fourth leading cause of cancer deaths in the United States.
The Pancreatic Cancer Biomarker Development Project is a Consortium representing four leading cancer research organizations, including Canary Foundation, Dana-Farber Cancer Institute, University of California at San Francisco and Van Andel Research Institute. The Project is expected to complete by the end of 2009. The Lustgarten Foundation is receiving support for the Project from the Harry T. Barbaris, M.D. Memorial Fund.
Said Dr. Robert Vizza, President of The Lustgarten Foundation, "Today,
it is widely accepted that certain proteins (biomarkers) tend to be
elevated in pancreatic cancer. Biomarkers show particular promise for the
early detection of pancreatic cancer because they can be detected in the
|SOURCE The Lustgarten Foundation for Pancreatic Cancer Research|
Copyright©2008 PR Newswire.
All rights reserved